Tapering from Methadone or Buprenorphine during Pregnancy: Maternal and Neonatal Outcomes in Norway 1996-2009

European Addiction Research

Volumn 21, Issue 5, 2015, Pages 253-261

  Welle Strand, Gabrielle K ^a,b   Skurtveit, Svetlana ^a,c   Tanum, Lars ^a,d   Waal, Helge ^a   Bakstad, Brittelise ^b   Bjarkø, Lisa ^e   Ravndal, Edle ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b Norwegian Directorate of Health   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Buprenorphine; Methadone; Norway; Pregnancy; Tapering

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; BIRTH WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MONITORING; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MATERNAL CARE; OPIATE ADDICTION; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; QUESTIONNAIRE; WELLBEING; ADVERSE EFFECTS; DRUG ADMINISTRATION; DRUG EFFECTS; EPIDEMIOLOGY; MALE; NEWBORN; NORWAY; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

ADULT; BIRTH WEIGHT; BUPRENORPHINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT, NEWBORN; MALE; METHADONE; NARCOTIC ANTAGONISTS; NARCOTICS; NORWAY; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84929672087     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000381670     Document Type: Article

References (41)

1. World Health Organization: Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, WHO, 2009.
2. Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, Stine SM, O'Grady KE, Arria AM, Fischer G: Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008; 35: 245-259.
3. Jansson LM, Velez M, Harrow C: The opioidexposed newborn: assessment and pharmacologic management. J Opioid Manag 2009; 5: 47-55.
4. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP: Neonatal abstinence syndrome: assessment and management. Addict Dis 1975; 2: 141-158.
5. McCarthy JJ: Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? J Matern Fetal Neonatal Med 2012; 25: 109-112.
6. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Jansson L, Fischer G: Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? J Matern Fetal Neonatal Med 2012; 25: 1197-1201.
7. World Health Organization: Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy. Geneva, WHO, 2014.
8. Medication-Assisted Treatment for Opioid Addiction during Pregnancy. Rockville, Substance Abuse and Mental Health Services Administration, 2005.
9. National Clinical Guidelines for the Management of Drug Use during Pregnancy, Birth and the Early Development Years of the Newborn. New South Wales Government, Drug & Alcohol Office, 2006.
10. Hepburn M: Drug use in pregnancy. Br J Hosp Med 1993; 49: 51-55.
11. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr: Opioid detoxification in pregnancy. Obstet Gynecol 1998; 92: 854-858.
12. Stewart RD, Nelson DB, Adhikari EH, McIntire DD, Roberts SW, Dashe JS, Sheffield JS: The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol 2013; 209: 267.e1-e5.
13. Luty J, Nikolaou V, Bearn J: Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2003; 24: 363-367.
14. Jones HE, O'Grady KE, Malfi D, Tuten M: Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008; 17: 372-386.
15. McGlone L, Hamilton R, McCulloch DL, MacKinnon JR, Bradnam M, Mactier H: Visual outcome in infants born to drug-misusing mothers prescribed methadone in pregnancy. Br J Ophthalmol 2014; 98: 238-245.
16. Hamilton R, McGlone L, MacKinnon JR, Russell HC, Bradnam MS, Mactier H: Ophthalmic, clinical and visual electrophysiological findings in children born to mothers prescribed substitute methadone in pregnancy. Br J Ophthalmol 2010; 94: 696-700.
17. Melinder A, Konijnenberg C, Sarfi M: Deviant smooth pursuit in preschool children exposed prenatally to methadone or buprenorphine and tobacco affects integrative visuomotor capabilities. Addiction 2013; 108: 2175-2182.
18. Jones HE, Jansson LM, O'Grady KE, Kaltenbach K: The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicol Teratol 2013; 39: 110-115.
19. Jones HE, Dengler E, Garrison A, O'Grady KE, Seashore C, Horton E, Andringa K, Jansson LM, Thorp J: Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug Alcohol Depend 2014; 134: 414-417.
20. Dryden C, Young D, Hepburn M, Mactier H: Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG 2009; 116: 665-671.
21. Cleary BJ, Donnelly JM, Strawbridge JD, Gallagher PJ, Fahey T, White MJ, Murphy DJ: Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011; 204: 139.e1-e9.
22. Cleary BJ, Donnelly J, Strawbridge J, Gallagher PJ, Fahey T, Clarke M, Murphy DJ: Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 2010; 105: 2071-2084.
23. Cleary BJ, Reynolds K, Eogan M, O'Connell MP, Fahey T, Gallagher PJ, Clarke T, White MJ, McDermott C, O'Sullivan A: Methadone dosing and prescribed medication use in a prospective cohort of opioid-dependent pregnant women. Addiction 2013; 108: 762-770.
24. Blinick G, Wallach RC, Jerez E: Pregnancy in narcotics addicts treated by medical withdrawal. The methadone detoxification program. Am J Obstet Gynecol 1969; 105: 997-1003.
25. Rementeria JL, Nunag NN: Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. Am J Obstet Gynecol 1973; 116: 1152-1156.
26. Lund IO, Fitzsimons H, Tuten M, Chisolm MS, O'Grady KE, Jones HE: Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse Rehabil 2012; 3(suppl 1):17-25.
27. Welle-Strand GK, Bakstad B: National Clinical Guideline for Opioid Maintenance Treatment in Pregnancy and the Follow-Up of the Children and Families until School-Age. Oslo, Norwegian Directorate of Health, 2011.
28. Welle-Strand GK, Kvamme O, Andreassen A, Ravndal E: A woman's experience of tapering from buprenorphine during pregnancy. BMJ Case Rep 2014; DOI: 10.1136/bcr-2014-207207.
29. Welle-Strand GK, Skurtveit S, Jones HE, Waal H, Bakstad B, Bjarko L, Ravndal E: Neonatal outcomes following in utero exposure to methadone or buprenorphine: a national cohort study of opioid-agonist treatment of pregnant women in Norway from 1996 to 2009. Drug Alcohol Depend 2013; 127: 200-206.
30. Welle-Strand GK, Waal H: Guidance for Medication Assisted Rehabilitation in Pregnancy (Norwegian Only). Oslo, National Center for Opioid Maintenance Treatment, 2001.
31. Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E: Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res 2009; 15: 128-134.
32. Welle-Strand GK: Questionnaire for Pregnancy/Birth in Opioid Maintenance Treatment (OMT) (Norwegian Only). Oslo, National Center for Opioid Maintenance Treatment, 1999.
33. Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, et al: Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011; 68: 1238-1246.
34. Calsyn DA, Malcy JA, Saxon AJ: Slow tapering from methadone maintenance in a program encouraging indefinite maintenance. J Subst Abuse Treat 2006; 30: 159-163.
35. Kornor H, Waal H: From opioid maintenance to abstinence: a literature review. Drug Alcohol Rev 2005; 24: 267-274.
36. Kornor H, Waal H, Sandvik L: Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status. Drug Alcohol Rev 2007; 26: 135-141.
37. Clausen T, Anchersen K, Waal H: Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008; 94: 151-157.
38. Cousins G, Teljeur C, Motterlini N, McCowan C, Dimitrov BD, Fahey T: Risk of drugrelated mortality during periods of transition in methadone maintenance treatment: a cohort study. J Subst Abuse Treat 2011; 41: 252-260.
39. Mulder EJ, Robles de Medina PG, Huizink AC, Van den Bergh BR, Buitelaar JK, Visser GH: Prenatal maternal stress: effects on pregnancy and the (unborn) child. Early Hum Dev 2002; 70: 3-14.
40. Weinstock M: The long-term behavioural consequences of prenatal stress. Neurosci Biobehav Rev 2008; 32: 1073-1086.
41. Brunton PJ: Effects of maternal exposure to social stress during pregnancy: consequences for mother and offspring. Reproduction 2013; 146:R175-R189.